Efficacy of Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Trials.
Xiang-Hui Mei, Tong Zhang, Yan Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis of six randomized controlled trials assessed mesenchymal stem cell (MSC) therapy for diabetic foot ulcers. MSC treatment was associated with a higher rate of complete healing than control (RR = 1.63, 95% CI: 1.23-2.16; P = .0007). The benefit was evident for ulcers smaller than 5 cm², but not for ulcers of 5 cm² or larger. The analysis found no significant differences in amputation risk, serious adverse events, or recurrence, so evidence of improved wound closure did not establish benefits for these other outcomes.
Key findings
- Across six RCTs, MSC therapy improved complete healing rates (RR = 1.63, 95% CI: 1.23-2.16; P = .0007).
- For ulcers <5 cm², healing was higher with MSC therapy (RR = 1.71, 1.11-2.63, P = .02); no significant effect was found for ulcers ≥5 cm² (RR = 1.18, 0.75-1.86, P = .46).
- No significant differences were reported for amputation risk (P = .16), serious adverse events (P = .38), or recurrence (P = .33).
Why it matters
Complete wound closure is a clinically relevant outcome in diabetic foot ulcer care, and this pooled evidence suggests MSC-based therapy may improve healing, particularly in smaller ulcers. However, the findings do not show reduced amputation, recurrence, or serious adverse events. The distinction between ulcer-size subgroups is important when interpreting the potential benefit and highlights uncertainty about which patients may benefit.
What to keep in mind
The meta-analysis included only six RCTs, and the abstract calls for multicenter phase III trials with standardized protocols, indicating that the evidence remains limited.